Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients
with early stage breast cancer (ESBC) and to estimate the pathologic complete response rate
to neoadjuvant anthracycline-based and non-platinum containing chemotherapy in patients with
triple-negative breast cancer who have received the IRX-2 Regimen before chemotherapy.